Global Dilated cardiomyopathy (DCM) Therapeutics Market Size, Share & Trends Analysis Report By Drug Class (Angiotensin-Converting Enzyme (ACE) Inhibitors, Beta Blockers, Aldosterone Antagonists, Digitalis, Angiotensin II Receptor Blockers, and Anticoagulants), By Therapy Device (Implantable Cardioverter-Defibrillators (ICDs), Biventricular Pacemakers, and Heart Pumps), Forecast Period (2020-2026).
The global DCM therapeutics market is anticipated to grow at a CAGR 8% during the forecast period. DCM is the most commonly occurring disease in adults aged 20 to 60. It started by affecting the heart's ventricles and atria that is the lower and upper chambers of the heart. The major factor contributing to the growth of the DCM therapeutics include the recent ongoing advancements in the therapies and treatment approaches.
The global DCM therapeutics market is segmented based on the drug class and therapy devices. Based on the drug class, the market is sub-segmented into angiotensin-converting enzyme (ACE) inhibitors, beta-blockers, aldosterone antagonists, digitalis, angiotensin II receptor blockers, and anticoagulants. Further, based on the therapy devices, the market is sub-segmented into implantable cardioverter-defibrillators (ICDs), biventricular pacemakers, and heart pumps.
The global DCM therapeutics market is further segmented based on geography into North America, Europe, Asia-Pacific, and the Rest of the World. North America is expected to show significant growth in the market during the forecast period. The growth in the region is owing to the growing number of heart disease in both adults and children across the region.
The key players of the global DCM therapeutics market include CENTOGENE N.V., Heartseed Inc., MyoKardia, Inc., Vericel Corp., Zensun (Shanghai) Sci & Tech Co., Ltd., Pfizer Inc., Renovacor, Inc., and others. The market players are considerably contributing to the market growth by the adoption of various strategies including merger & acquisition, collaborations with government, funding, new drug launches, and various other advancements to stay competitive in the market.
Research Methodology:
The market study of the global DCM therapeutics market is incorporated by extensive primary and secondary research. Secondary research has been conducted to refine the available data to breakdown the market in various segments, derive total market size, market forecast, and growth rate. Different approaches have been worked on to derive the market value and market growth rate. The team collects facts and data related to the market from different geography to provide a better regional outlook. In the report, the country-level analysis is provided by analyzing various regional players, regional tax laws and policies, consumer behavior, and macro-economic factors. Numbers extracted from secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables the analyst to derive the closest possible figures without any major deviations in the actual number. The analysts try to contact as many executives, managers, key opinion leaders, and industry experts. Primary research brings authenticity to the reports.
Secondary Sources Include:
The report is intended for the drug manufacturers, hospitals & clinics, and other related industries for overall market analysis and competitive analysis. The report provides an in-depth analysis of market size, products offered by the companies, and future market opportunities. The report will serve as a source for a 360-degree analysis of the market thoroughly delivering insights into the market for making better business decisions.
Market Segmentation:
1. Global DCM Therapeutics Market Research and Analysis by Drug Class
2. Global DCM Therapeutics Market Research and Analysis by Therapy Device
The Report Covers:
The global DCM therapeutics market is anticipated to grow at a CAGR 8% during the forecast period. DCM is the most commonly occurring disease in adults aged 20 to 60. It started by affecting the heart's ventricles and atria that is the lower and upper chambers of the heart. The major factor contributing to the growth of the DCM therapeutics include the recent ongoing advancements in the therapies and treatment approaches.
The global DCM therapeutics market is segmented based on the drug class and therapy devices. Based on the drug class, the market is sub-segmented into angiotensin-converting enzyme (ACE) inhibitors, beta-blockers, aldosterone antagonists, digitalis, angiotensin II receptor blockers, and anticoagulants. Further, based on the therapy devices, the market is sub-segmented into implantable cardioverter-defibrillators (ICDs), biventricular pacemakers, and heart pumps.
The global DCM therapeutics market is further segmented based on geography into North America, Europe, Asia-Pacific, and the Rest of the World. North America is expected to show significant growth in the market during the forecast period. The growth in the region is owing to the growing number of heart disease in both adults and children across the region.
The key players of the global DCM therapeutics market include CENTOGENE N.V., Heartseed Inc., MyoKardia, Inc., Vericel Corp., Zensun (Shanghai) Sci & Tech Co., Ltd., Pfizer Inc., Renovacor, Inc., and others. The market players are considerably contributing to the market growth by the adoption of various strategies including merger & acquisition, collaborations with government, funding, new drug launches, and various other advancements to stay competitive in the market.
Research Methodology:
The market study of the global DCM therapeutics market is incorporated by extensive primary and secondary research. Secondary research has been conducted to refine the available data to breakdown the market in various segments, derive total market size, market forecast, and growth rate. Different approaches have been worked on to derive the market value and market growth rate. The team collects facts and data related to the market from different geography to provide a better regional outlook. In the report, the country-level analysis is provided by analyzing various regional players, regional tax laws and policies, consumer behavior, and macro-economic factors. Numbers extracted from secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables the analyst to derive the closest possible figures without any major deviations in the actual number. The analysts try to contact as many executives, managers, key opinion leaders, and industry experts. Primary research brings authenticity to the reports.
Secondary Sources Include:
- Financial reports of companies involved in the market.
- Whitepapers, research-papers, and news blogs.
- Company websites and their product catalog.
The report is intended for the drug manufacturers, hospitals & clinics, and other related industries for overall market analysis and competitive analysis. The report provides an in-depth analysis of market size, products offered by the companies, and future market opportunities. The report will serve as a source for a 360-degree analysis of the market thoroughly delivering insights into the market for making better business decisions.
Market Segmentation:
1. Global DCM Therapeutics Market Research and Analysis by Drug Class
2. Global DCM Therapeutics Market Research and Analysis by Therapy Device
The Report Covers:
- Comprehensive research methodology of the global DCM therapeutics market.
- This report also includes a detailed and extensive market overview with key analyst insights.
- An exhaustive analysis of macro and micro factors influencing the market guided by key recommendations.
- Analysis of regional regulations and other government policies impacting the global DCM therapeutics market.
- Insights about market determinants which are stimulating the global DCM therapeutics market.
- Detailed and extensive market segments with regional distribution of forecasted revenues.
- Extensive profiles and recent developments of market players.
Table of Contents
1. Report Summary
2. Market Overview and Insights
3. Competitive Landscape
4. Market Determinants
5. Market Segmentation
6. Regional Analysis
7. Company Profiles
Companies Mentioned
A selection of companies mentioned in this report includes:
- Abbott Laboratories
- Berlin Cures GmbH
- Capricor Therapeutics, Inc.
- Cardiol Therapeutics Inc.
- Celixir plc
- CENTOGENE N.V.
- Heartseed Inc.
- Medtronic plc
- Merck & Co., Inc.
- MyoKardia, Inc.
- Novartis AG
- Pfizer Inc.
- Renovacor, Inc.
- Sanofi SA
- Tenaya Therapeutics
- Vericel Corp.
- Zecardio Therapeutics SL
- Zensun (Shanghai) Sci & Tech Co., Ltd.